Department of Pathology, Fifth School of Clinical Medicine of Zhejiang, Huzhou Central Hospital, Chinese Medical University, Huzhou, People's Republic of China.
Department of Pathology, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, People's Republic of China.
Diagn Pathol. 2024 Jun 10;19(1):77. doi: 10.1186/s13000-024-01504-2.
Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments. Immunotherapy is a promising avenue for the treatment of advanced thyroid carcinoma. B7-H3 (B7 homolog 3 protein) and ICAM-1 (intercellular adhesion molecule 1), as two important immune checkpoints (ICPs), is becoming hopeful target spots for immunotherapy. A growing amount of evidence has suggested that B7-H3 and ICAM-1 are upregulated in papillary thyroid carcinoma. However, their expression level in specific types of thyroid cancer remains largely unclear. In the present study, we explored the expression level of B7-H3 and ICAM-1 in different types of thyroid carcinoma. In the groups of the TCGA cohort, both B7-H3 and ICAM-1 mRNA were highly expressed in thyroid carcinoma. Furthermore, the patients with Stage2, 61-80y, Follicular thyroid papillary carcinoma and N0 had lower B7-H3 and ICAM-1 mRNA expression. In the groups of our cohort, PTCs and ATCs showed frequently moderate to strong expression of B7-H3 and ICAM-1 protein expression. The significant relevance of B7-H3 staining score with ICAM-1 staining score was observed in TCGA database and our cohort, which might open avenues for the combination therapy in advanced thyroid cancer.
虽然大多数分化型甲状腺癌具有临床预后良好，但某些特定类型的甲状腺癌（如间变性甲状腺癌和晚期甲状腺乳头状癌）表现出致命的结局，需要新的治疗方法。免疫疗法是治疗晚期甲状腺癌的一种有前途的途径。B7-H3（B7 同源物 3 蛋白）和 ICAM-1（细胞间黏附分子 1）作为两个重要的免疫检查点（ICPs），正成为免疫治疗的有希望的靶点。越来越多的证据表明，B7-H3 和 ICAM-1 在甲状腺乳头状癌中上调。然而，它们在特定类型的甲状腺癌中的表达水平仍很大程度上不清楚。在本研究中，我们探讨了 B7-H3 和 ICAM-1 在不同类型的甲状腺癌中的表达水平。在 TCGA 队列的组中，B7-H3 和 ICAM-1 的 mRNA 在甲状腺癌中均高表达。此外，在分期为 2 期、年龄 61-80 岁、滤泡状甲状腺乳头状癌和 N0 的患者中，B7-H3 和 ICAM-1 mRNA 的表达较低。在我们队列的组中，PTCs 和 ATCs 显示出 B7-H3 和 ICAM-1 蛋白表达的中度至强表达。在 TCGA 数据库和我们的队列中观察到 B7-H3 染色评分与 ICAM-1 染色评分之间的显著相关性，这可能为晚期甲状腺癌的联合治疗开辟了途径。
